King Hussein Cancer Center

Running trials

• Recruiting

  HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC)

  NCT07801235· King Hussein Cancer Center· Source

• Recruiting

  Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

  NCT06528691· Phase 2· St. Jude Children's Research Hospital· Source

• Recruiting

  MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

  NCT07371403· King Hussein Cancer Center· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· PharmaEssentia· Source

• Recruiting

  IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

  NCT06713837· Phase 3· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

• Recruiting

  Master Framework For Relapse or Refractory Acute Myeloid Leukemia

  NCT06459024· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

• Active, not recruiting

  ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

  NCT05653063· University College, London· Source

• Active, not recruiting

  A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

  NCT06054555· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

  NCT04603807· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

  NCT04127110· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Active, not recruiting

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  EORTC Metastatic Breast Cancer Module Development

  NCT07806266· University of Leeds· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers3 recruiting
• Acute myeloid leukaemia2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Head and neck cancer1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  RESPECT: (REsearching Stigma in PEdiatric Cancer Tool)

  NCT06470230· St. Jude Children's Research Hospital· Source

• Terminated

  A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma

  NCT04780464· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Completed

  Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

  NCT04937660· Pfizer· Source

• Completed

  Follow-up in Early and Locally Advanced Breast Cancer Patients

  NCT03859453· European Organisation for Research and Treatment of Cancer - EORTC· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Acute lymphoblastic leukaemia12 works · 1 trial
• Childhood cancers11 works · 4 trials
• Hodgkin lymphoma11 works · 0 trials
• Thyroid cancer9 works · 0 trials